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CASE REPORT
Citrullinemia is a metabolic disorder characterized
by elevated plasma concentrations of citrulline
and ammonia, which is caused by a deficiency of
argininosuccinate synthetase (ASS), one of the five
urea cycle enzymes.1 This disorder can be classi-
fied into three types: neonatal/infantile (types I
and III) and adult (type II). Classical citrullinemia
(types I and III, CTLN1) is neonatal or infantile in
onset, with ASS enzyme defects (in all tissues)
arising due to mutations in ASS on chromosome
9q34. Adult-onset citrullinemia (type II, CTLN2)
fis characterized by a liver-specific deficiency o
ASS protein, caused by mutations in the “citrin
gene” (SLC25A13) on chromosome 7q21.3.2 yFatt
liver has been frequently found on liver histol-
ogy in patients with CTLN2. A high incidence 
of hepatocellular carcinoma (HCC) is found in
patients with CTLN2 and most of the reported
cases are from Japan.3 Only one case of adult-
onset citrullinemia has been previously reported
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Citrullinemia is a metabolic disorder characterized by elevated plasma concentrations of citrulline and
yammonia. Adult-onset citrullinemia (type II, CTLN2) has been attributed to citrin deficiency caused b
mutations in the SLC25A13 gene. CTLN2 is associated with a high incidence of hepatocellular carcinoma
(HCC) in Japanese. We report a 48-year-old Taiwanese man with citrullinemia, who was in good health
until the age of 34 when he had repeated episodes of consciousness disturbance. Hyperammonia
(201 μ tmol/L) was found during an episode of coma. Liver function and electrolyte levels were normal a
that time. Serologic markers of viral hepatitis B and C were negative. Analysis of genomic DNA extracted
from peripheral blood leukocytes showed homozygous 851del4 mutation in exon 9 of the SLC25A13
gene on chromosome 7q21.3. Fourteen years after disease onset, at the age of 48, he was admitted due to
an episode of coma. Abdominal sonography and computed tomography showed a 2.5 cm tumor in the
left lobe of the liver, without evidence of liver cirrhosis. Wedge resection of the tumor was performed and
grade 2 HCC was diagnosed. The nontumor part of the resected specimen showed chronic persistent hep-
atitis with moderate steatosis. The results in this case support that both citrin deficiency and steatohepati-
tis may contribute to hepatocarcinogenesis. [J Formos Med Assoc 2006;105(10):852–856]
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from Taiwan.4,5 Here, we describe a Taiwanese
man with CTLN2 with homozygous 851del4 of
the SLC25A13 gene. The patient had repeated
episodes of consciousness disturbance. HCC was
found in this patient 14 years after disease onset.
Case Report
A 48-year-old Taiwanese man was in good health
until the age of 34 when he had repeated episodes
of consciousness disturbance. Each episode began
with incoherent speech, bizarre behaviors, confu-
sion and then progressed to a deep sleep state with
urinary and stool incontinence. The duration of
each episode lasted from 4 to 24 hours. The fre-
quency had increased to almost once a day when
he was sent to our hospital at the age of 42. No
focal neurologic defect was noted during attack-free
periods. Elevation of ammonia (201μmol/L) and
lactate acid (3.8mmol/L) was found during an
episode of coma. Liver function and electrolyte lev-
els were normal at that time. Abdominal sonogra-
phy showed fatty liver but no other abnormalities.
Serologic markers of viral hepatitis B and C (hepa-
titis B surface antigen, hepatitis B surface antibody,
hepatitis C virus antibody) were negative. Genera-
lized slow waves with intermittent triphasic waves
without epileptiform discharges in electroencep-
halogram (EEG) were observed. Urea cycle disor-
der was suspected and plasma amino acid analysis
showed elevated citrulline (1302 μmol/L; nor-
mal, 25–75 μmol/L) and arginine (1199 μmol/
L; normal, 13–103 μmol/L). Citrullinemia was
impressed. Genomic DNA was extracted from
peripheral blood leukocytes and homozygous
851del4 mutations were found in exon 9 of the
SLC25A13 gene, the culprit mutation for adult-
onset citrullinemia on chromosome 7q21.3
(Figure 1). He had been prescribed a low protein
diet and sodium phenylbutyrate, and had attended
tregular follow-up at the outpatient departmen
since 1999.
In 2004, at the age of 48, 14 years after disease
fonset, he was admitted due to another episode o
coma. Hyperammonia (483 μmol/L) was found
and emergent hemodialysis was performed. His
consciousness recovered fully 12 hours after he-
modialysis. During hospitalization, liver function
test showed aspartate aminotransferase, 66 U/L;
alanine aminotransferase, 54 U/L; alkaline phos-
phatase, 312 U/L; gamma-glutamic transpeptidase,
70 U/L; total bilirubin, 0.73 mg/dL; albumin,
4.0 g/dL. Abdominal sonography showed a 2.5 cm
tumor in the left lobe of the liver without liver cir-
Lrhosis. Serum alpha-fetal protein was 23.4 ng/d
(normal, <20 ng/dL). Abdominal computed to-
mography showed a hypervascular tumor at the
hepatic dome in the arterial phase (Figure 2).
Cytology of fine needle aspiration led to the di-
ragnosis of HCC. Wedge resection of the tumo
was performed and histology of the resected
specimen showed a grade 2 HCC (Figure 3A).
The nontumor part of the resected specimen
showed chronic persistent hepatitis with mod-
erate fatty change (40–50%), both micro- and
macrosteatosis (Figure 3B). The patient recovered
uneventfully after operation.
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Discussion
Although hyperammonemia frequently devel-
ops in patients with decompensated liver (viral,
alcohol-induced), there are several other causes
of hyperammonemia. Differential diagnoses can
be divided into two major categories: (1) inherited
disorders, such as metabolic disorders (urea cycle
defects, organic acidemias, fatty acid oxidation
disorders, pyruvate metabolism defects, etc.) and
congenital defects associated with liver failure
(Wilson’s disease, biliary atresia); and (2) acquired
disorders, such as Reye’s syndrome, drug ingestion
or chemical-induced liver failure, high-dose che-
motherapy, sepsis, transient hyperammonemia of
the newborn, and urinary tract infection associated
with congenital ureteral obstruction.6 In addition,
a few cases of hyperammonemia caused by por-
tosystemic shunts in patients without cirrhosis
and portal hypertension have been reported.7
Hyperammonemia in our patient was attributed
to citrullinemia, one of the urea cycle enzyme-
related metabolic disorders.
Adult-onset citrullinemia (CTLN2) is caused
 by mutations in the SLC25A13 gene, which
rencodes a mitochondrial calcium-binding carrie
protein named citrin.2 This disorder was first re-
ported by Miyakoshi et al in 1968. Most reported
cases are from Japan. Several mutations of the
SLC25A13 gene have been identified in Japanese
patients with CTLN2.8 Only one case from Taiwan
has been previously reported.4,5
fThese patients present with sudden onset o
consciousness disturbance, such as disorientation,
abnormal behavior, drowsiness and even coma
in patients with more advanced disease. The bio-
chemical findings in patients with CTLN2 include
elevated plasma ammonia, citrulline and arginine,
increased urinary argininosuccinate excretion, hy-
pertriglyceridemia, and elevated levels of serum
pancreatic secretory trypsin inhibitor.2 Reported
rvisceral organ lesions include severe fatty live
and chronic pancreatitis.7,8
Our patient had fatty liver with steatohepatitis
in the nontumor part of the surgical specimen.
Liver histology in CTLN2 varies from steatosis,
BA
iF gure 3. f ’ f(A) Specimen o  liver wedge resection shows an Edmondson s classi ication grade II hepatocellular carcinoma.
Noncapsulated trabecularly arranged tumor cells show focal cytoplasmic fatty change; high power magnification of the
tumor cells (inset) shows fatty change. Nontumor part (*) (hematoxylin & eosin, original magnification, 200˜; inset,
400˜). (B) Micro- and macrovesicular fatty changes without evident fibrosis in the nontumor part (hematoxylin & eosin,
original magnification, 400˜).
iF gure 2.  Abdominal computed tomography shows a
hypervascular tumor at the hepatic dome in the arterial
phase (arrow).
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severe fatty metamorphosis, to slight or moderate
fibrotic changes.7 Recent studies showed that cit-
rin deficiency causes two different phenotypes:
neonatal intrahepatic cholestasis caused by citrin
deficiency in neonates and CTLN2 in adults.
Fatty liver is usually seen in either phenotype
of citrin deficiency, as well as either type of cit-
rullinemia.11 It is probable that excessive serum
citrulline may lead to fatty change.
HCC had been reported in Japanese patients
with adult-onset citrullinemia before the identi-
fication of the citrin gene.3 However, previous case
reports did not mention the association between
the “citrin gene” (SLC25A13) and HCC.12,13 This
is the first case report of CTLN2 with HCC from
Taiwan. Several potential mechanisms linking
citrullinemia to hepatocarcinogenesis have been
proposed. High incidences of ASS deficiency, one
of the core features of citrullinemia, have recently
been documented in HCC.14 In vitro study has
shown that excessive citrulline can promote pro-
liferation of hepatocytes, which might lead to
hepatocarcinogenesis.3 In addition, citrin defi-
ciency can block the malate aspartate shuttle,
resulting in an increased cytosolic nicotinamide
adenine dinucleotide dehydrogenase (NADH) to
nicotinamide adenine dinucleotide (NAD+) ratio.
Increased cytosolic NADH would then cause the
so-called reductive stress and subsequent oxida-
tive stress, both of them leading to liver dam-
age.1,11 Finally, free fatty acids accumulate in the
liver through altered fat homeostasis and oxida-
tive stress, and lipid peroxidation may play a role
in the liver damage, as seen in nonalcoholic
steatohepatitis (NASH) and citrullinemia-related
steatohepatitis.1
It has been known that patients with steatosis
can develop progressive liver disease, cirrhosis
and even HCC. Eleven cases of HCC associated
with NASH (nine cases from Japan) have been
reported.15,16 The median age at diagnosis of
HCC was 66.6 years. All 11 patients had cirrhosis
when HCC was found, but our patient did not
have liver cirrhosis. Other reported cases of HCC
and type II citrullinemia tended to be in young
patients without liver cirrhosis.3 Thus, the hepa-
ytocarcinogenesis in citrullinemia patients ma
not be solely due to steatosis-induced cirrhosis.
The contribution of ASS deficiency and citrin de-
ficiency with excessive blood citrulline to hepa-
tocarcinogenesis remains unclear and need to be
studied further.
References
1. Saheki T, Kobayashi K. Mitochondrial aspartate glutamate
carrier (citrin) deficiency as the cause of adult-onset type
II citrullinemia (CTLN2) and idiopathic neonatal hepatitis
(NICCD). J Hum Genet 2002;47:333–41.
2. Kobayashi K, Sinasac DS, Iijima M, et al. The gene
mutated in adult-onset type II citrullinemia encodes a pu-
tative mitochondrial carrier protein. Nat Genet 1999;22:
159–63.
3. Nkamura M, Okamoto Y, Morita T, et al. Promoting effect
of citrullinemia in hepatocarcinogenesis: possible mecha-
nisim in hypercitrullinemia. Hepatology 1990;11:819–23.
4. Hwu WL, Kobayashi K, Hu YH, et al. A Chinese adult
onset type II citrullinaemia patient with 851del4/1638ins23
mutations in the SLC25A13 gene. J Med Genet 2001;
38:23.
5. Chen YF, Huang YC, Liu HM, et al. MRI in a case of adult-
onset citrullinemia. Neuroradiology 2001;43:845–7.
6. Mathias RS, Kostiner D, Packman S. Hyperammonemia in
urea cycle disorders: role of the nephrologist. Am J Kidney
Dis 2001;37:1069–80.
7. Caturelli E, Ghittoni G, Niro GA, et al. Multiple intrahep-
atic vascular shunts causing hyperammoniaemic encephalo-
pathy in a patient without liver cirrhosis. Dig Liver Dis 2006;
38:347–51.
8. Kobayashi K, Lu YB, Li MX, et al. Screening of nine
SLC25A13 mutations: their frequency in patients with citrin
deficiency and high carrier rates in Asian populations. Mol
Genet Metab 2003;80:356–9.
9. Ikeda S, Yazaki M, Takei Y, et al. Type II (adult onset) cit-
frullinaemia: clinical pictures and the therapeutic effect o
liver transplantation. J Neurol Neurosurg Psychiatry 2001;
71:663–70.
10. Ikeda S, Kawa S, Takei Y, et al. Chronic pancreatitis asso-
ciated with adult-onset type II citrullinemia: clinical and
pathologic findings. Ann Intern Med 2004;141:109–10.
11. Saheki T, Kobayashi K, Iijima M, et al. Adult-onset type II
citrullinemia and idiopathic neonatal hepatitis caused by
citrin deficiency: involvement of the aspartate glutamate
carrier for urea synthesis and maintenance of the urea
cycle. Mol Genet Metab 2004;8:20–6.
12. Hagiwara N, Sekijima Y, Takei Y, et al. Hepatocellular car-
cinoma in a case of adult-onset type II citrullinemia. Intern
Med 2003;42:978–82.
13. Ito T, Shiraki K, Sekoguchi K, et al. Hepatocellular carci-
noma associated with adult-type citrullinemia. Dig Dis Sci
2000;45:2203–6.
14. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distri-
bution of argininosuccinate synthetase deficiency in human
cancers: a method for identifying cancers sensitive to argi-
nine deprivation. Cancer 2004;100:826–33.
15. Yoshioka Y, Hashimoto E, Yatsuji S, et al. Nonalcoholic
steatohepatitis: cirrhosis, hepatocellular carcinoma, and
burnt-out NASH. J Gastroenterol 2004;39:1215–18.
16. Mori S, Yamasaki T, Sakaida I, et al. Hepatocellular carci-
noma with nonalcoholic steatohepatitis. J Gastroenterol
2004;39:391–6.
C.W. Tsai, et al
856 J Formos Med Assoc | 2006 • Vol 105 • No 10
